辉瑞公布TALAPRO-2研究最新数据 泰泽纳与恩扎卢胺联合疗法有望成为改变临床实践治疗方案

中国网财经
14 Feb

中国网财经2月14日讯 辉瑞公司(NYSE:PFE)昨日宣布,TALAPRO-2 III期临床研究取得积极结果。该研究旨在评估口服聚腺苷二磷酸核糖聚合酶(PARP)抑制剂泰泽纳(甲苯磺酸他拉唑帕利胶囊)联合雄激素受体通路抑制剂(ARPI)恩扎卢胺治疗转移性去势抵抗性前列腺癌(mCRPC)的有效性和安全性。与接受安慰剂联合恩扎卢胺治疗的患者相比,接受泰泽纳联合恩扎卢胺治疗的mCRPC患者,无论是否...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10